Portopulmonary hypertension: A tale of two circulations

Chest

Volumn 123, Issue 2, 2003, Pages 562-576

  Budhiraja, Rohit ^a   Hassoun, Paul M ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelin; Liver; Nitric oxide; Portal hypertension; Portopulmonary hypertension; Prostacyclin; Pulmonary hypertension; Serotonin; Transplant

Indexed keywords

ARGININE; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPYRIDAMOLE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRATE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA; UNIPROST; VASODILATOR AGENT;

ARTERY RESISTANCE; AUTOIMMUNITY; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; ENDOTHELIUM; FOLLOW UP; GAS EXCHANGE; GENE MUTATION; GENETIC DISORDER; HEPATOPULMONARY SYNDROME; HISTOLOGY; HUMAN; LEUKOPENIA; LIVER METABOLISM; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG ARTERY; LUNG ARTERY PRESSURE; MEDIATOR; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PATIENT CARE; PERIOPERATIVE PERIOD; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCREENING; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0037332028     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.2.562     Document Type: Review

References (208)

1. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994; 105:37S-41S
2. Krowka MJ, McGoon MD. Portopulmonary hypertension: the next step. Chest 1997; 112:869-870
3. Kuo PC, Plotkin JS, Gaine S, et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999; 67:1087-1093
4. Mackworth-Young CG, Gharavi AE, Boey ML, et al. Portal and pulmonary hypertension in a case of systematic lupus erythematosus: possible relationship with a clotting abnormality. Eur J Rheumatol Inflamm 1984; 7:71-74
5. Bayraktar Y, Tanaci N, Egesel T, et al. Antiphospholipid syndrome presenting as portopulmonary hypertension. J Clin Gastroenterol 2001; 32:359-361
6. De Clerck LS, Michielsen PP, Ramael MR, et al. Portal and pulmonary vessel thrombosis associated with systemic lupus erythematosus and anticardiolipin antibodies. J Rheumatol 1991; 18:1919-1921
7. Sawai T, Tutikawa K, Watanabe T, et al. A case of mixed connective tissue disease (MCTD) complicating pulmonary hypertension and portal hypertension [in Japanese]. Ryumachi 1988; 28:164-169
8. Ozawa T, Nakagawa O, Hasegawa S, et al. A case of mixed connective tissue disease accompanied with idiopathic portal hypertension and pulmonary hypertension [in Japanese]. Nippon Naika Gakkai Zasshi 1989; 78:1799-1800
9. Chaves E. The pathology of the arterial pulmonary vasculature in Manson's schistosomiasis. Dis Chest 1966; 50:72-77
10. Emanuel A, Prata A, Bina JC, et al. Persistent schistosomal pulmonary hypertension in a patient after reversion of a hepato-splenic form: presentation of a case [in Portuguese]. Rev Soc Bras Med Trop 1986; 19:171-172
11. Watt G, Long GW, Calubaquib C, et al. Cardiopulmonary involvement rare in severe Schistosoma japonicum infection. Trop Geogr Med 1986; 38:233-239
12. Cornet A, Barbier JP, Debesse B, et al. Sarcoidosis and portal and pulmonary arterial hypertension: a case report [in French]. Ann Med Intern 1980; 131:431-434
13. Salazar A, Mana J, Sala J, et al. Combined portal and pulmonary hypertension in sarcoidosis. Respiration 1994; 61:117-119
14. Kuramochi S, Tashiro Y, Torikata C, et al. Systemic lupus erythematosus associated with multiple nodular hyperplasia of the liver. Acta Pathol Jpn 1982; 32:547-560
15. Ansari A, Larson PH, Bates HD. Vascular manifestations of systemic lupus erythematosus. Angiology 1986; 37:423-432
16. Pare PD, Chan-Yan C, Wass H, et al. Portal and pulmonary hypertension with microangiopathic hemolytic anemia. Am J Med 1983; 74:1093-1096
17. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 17:17-33
18. Mantz FA, Craig E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. Arch Pathol Lab Med 1951; 52:91-97
19. A fifty-six year old woman with jaundice and pulmonary hypertension. Am J Med 1969; 47:287-298
20. Levine OR, Harris RC, Blanc WA, et al. Progressive pulmonary hypertension in children with portal hypertension. J Pediatr 1973; 83:964-972
21. Lebrec D, Capron JP, Dhumeaux D, et al. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979; 120:849-856
22. Molden D, Abraham JL. Pulmonary hypertension: its association with hepatic cirrhosis and iron accumulation. Arch Pathol Lab Med 1982; 106:328-331
23. Wagenvoort CA. Medial defects of lung vessels: a new cause of pulmonary hypertension. Hum Pathol 1986; 17:722-726
24. Boot H, Visser FC, Thijs JC, et al. Pulmonary hypertension complicating portal hypertension: a case report with suggestions for a different therapeutic approach. Eur Heart J 1987; 8:656-660
25. Edwards BS, Weir EK, Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987; 10:1233-1238
26. Chan T, Palevsky HI, Miller WT. Pulmonary hypertension complicating portal hypertension: findings on chest radiographs. AJR Am J Roentgenol 1988; 151:909-914
27. Maev IV, Merzlikin LA, Vorob'ev LP, et al. Study of the right heart and external respiratory functions in patients with liver cirrhosis by Doppler echocardiography [in Russian]. Sov Med 1991; 8:11-13
28. Hadengue A, Benhayoun MK, Lebrec D, et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100:520-528
29. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17:492-498
30. Moscoso G, Mieli-Vergani G, Mowat AP, et al. Sudden death caused by unsuspected pulmonary arterial hypertension, 10 years after surgery for extrahepatic biliary atresia. J Pediatr Gastroenterol Nutr 1991; 12:388-393
31. Rossi SO, Gilbert-Barness E, Saari T, et al. Pulmonary hypertension with coexisting portal hypertension. Pediatr Pathol 1992; 12:433-439
32. Goenka MK, Mehta SK, Malik AK, et al. Fatal pulmonary arterial hypertension complicating noncirrhotic portal fibrosis. Am J Gastroenterol 1992; 87:1203-1205
33. Yoshida EM, Erb SR, Pflugfelder PW, et al. Single-lung vs liver transplantation for the treatment of portopulmonary hypertension: a comparison of two patients. Transplantation 1993; 55:688-690
34. Tokiwa K, Iwai N, Nakamura K, et al. Pulmonary hypertension as a fatal complication of extrahepatic portal hypertension. Eur J Pediatr Surg 1993; 3:373-375
35. Woolf D, Voigt MD, Jaskiewicz K, et al. Pulmonary hypertension associated with non-cirrhotic portal hypertension in systemic lupus erythematosus. Postgrad Med J 1994; 70:41-43
36. Yoshida EM, Erb SR, Ostrow DN, et al. Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension: a case report. Gut 1994; 35:280-282
37. Koneru B, Ahmed S, Weisse AB, et al. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994; 58:1133-1135
38. Tasaka S, Kanazawa M, Nakamura H, et al. An autopsied case of primary pulmonary hypertension complicated by hepatopulmonary syndrome [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33:90-94
39. Levy MT, Torzillo P, Bookallil M, et al. Case report: delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J Gastroenterol Hepatol 1996; 11:734-737
40. Kuo PC, Schroeder RA, Vagelos RH, et al. Volume-mediated pulmonary responses in liver transplant candidates. Clin Transplant 1996; 10:521-527
41. Murata K, Shimizu A, Takase K, et al. Asymptomatic primary pulmonary hypertension associated with liver cirrhosis. J Gastroenterol 1997; 32:102-104
42. Rich S. Primary pulmonary hypertension: executive summary from the world symposium. WHO Programme on Cardiovascular Diseases, 1998. Available at: http:/www.who.int/ncd/cvd/pph.html. Accessed December 15, 2001.
43. Cohen MD, Rubin LJ, Taylor WE, et al. Primary pulmonary hypertension: an unusual case associated with extrahepatic portal hypertension. Hepatology 1983; 3:588-592
44. Soh H, Hasegawa T, Sasaki T, et al. Pulmonary hypertension associated with postoperative biliary atresia: report of two cases. J Pediatr Surg 1999; 34:1779-1781
45. Klochkov SA, Alekseevskikh Iu G, Seniakovich VM. Histologic changes in the lungs and heart in children with extrahepatic blockade of the portal circulation [in Russian]. Arkh Patol 1996; 58:54-58
46. De BK, Pal A, Santra A, et al. Primary pulmonary hypertension in non-cirrhotic portal fibrosis. Indian J Gastroenterol 1997; 16:85-87
47. Sekiguchi Y, Amano K, Takano Y, et al. Portal and pulmonary hypertension in a patient with MCTD [in Japanese]. Ryumachi 1999; 39:657-663
48. Bernthal AC, Eybel CE, Payne JA. Primary pulmonary hypertension after portocaval shunt. J Clin Gastroenterol 1983; 5:353-356
49. Mikhel'son VA, Trifonova NA, Ismail-Zade IA, et al. Disorders of hemodynamics and their correction in children with nonhepatic portal hypertension during the course of surgical treatment [in Russian]. Anesteziol Reanimatol 1993:13-16
50. Ismail-Zade IA, Trifonova NA, Razumovski AY, et al. Haemodynamic changes in children with portal hypertension during the postoperative period. Paediatr Anaesth 1995; 5:311-317
51. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127:437-441
52. Sen S, Biswas PK, Biswas J, et al. Primary pulmonary hypertension in cirrhosis of liver. Indian J Gastroenterol 1999; 18:158-160
53. Yang YY, Lin HC, Lee WC, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001;36:181-186
54. Taura P, Garcia-Valdecasas JC, Beltran J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996; 83:675-680
55. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996; 71:543-551
56. Ramsay MA, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3:494-500
57. Donovan CL, Marcovitz PA, Punch JD, et al. Two-dimensional, and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996; 61:1180-1188
58. Auletta M, Oliviero U, Iasiuolo L, et al. Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. Angiology 2000; 51:1013-1020
59. Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112:980-986
60. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11:1153-1166
61. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-223
62. Weissman E, Becker NH. Interstitial lung disease in primary biliary cirrhosis. Am J Med Sci 1983; 285:21-27
63. Osaka M, Aramaki T, Okumura H, et al. Primary biliary cirrhosis with fibrosing alveolitis. Gastroenterol Jpn 1988; 23:457-460
64. Strobel ES, Bonnet RB, Werner P, et al. Bronchiolitis obliterans organising pneumonia and primary biliary cirrhosis-like lung involvement in a patient with primary biliary cirrhosis. Clin Rheumatol 1998; 17:246-249
65. Bissuel F, Bizollon T, Dijoud F, et al. Pulmonary hemorrhage and glomerulonephritis in primary biliary cirrhosis. Hepatology 1992; 16:1357-1361
66. Plauchu M, Chapuy H, de Montgolfier R, et al. Pleural effusions in liver cirrhosis (17 cases out of 508 cases of cirrhosis) [in French]. J Med Lyon 1970; 51:641-652
67. Valeriano V, Funaro S, Lionetti R, et al. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000; 95:3200-3205
68. Epstein SK, Ciubotaru RL, Zilberberg MD, et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci 1998; 43:1701-1707
69. Campillo B, Fouet P, Bonnet JC, et al. Submaximal oxygen consumption in liver cirrhosis: evidence of severe functional aerobic impairment. J Hepatol 1990; 10:163-167
70. Grose RD, Nolan J, Dillon JF, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995; 22:326-332
71. Cabre E, Gassull MA. Nutritional issues in cirrhosis and liver transplantation. Curr Opin Clin Nutr Metab Care 1999; 2:373-380
72. Roth K, Lynn J, Zhong Z, et al. Dying with end stage liver disease with cirrhosis: insights from SUPPORT; Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc 2000; 48:S122-S130
73. Agusti AG, Roca J, Rodriguez-Roisin R. Mechanisms of gas exchange impairment in patients with liver cirrhosis. Clin Chest Med 1996; 17:49-66
74. King PD, Rumbaut R, Sanchez C. Pulmonary manifestations of chronic liver disease. Dig Dis 1996; 14:73-82
75. Daoud FS, Reeves JT, Schaefer JW. Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. J Clin Invest 1972; 51:1076-1080
76. Albillos A, Rossi I, Cacho G, et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 1995; 268:G459-G464
77. Vachiery F, Moreau R, Hadengue A, et al. Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alterations. J Hepatol 1997; 27:492-495
78. Barbe T, Losay J, Grimon G, et al. Pulmonary arteriovenous shunting in children with liver disease. J Pediatr 1995; 126:571-579
79. Thorens JB, Junod AF. Hypoxaemia and liver cirrhosis: a new argument in favour of a "diffusion-perfusion defect." Eur Respir J 1992; 5:754-756
80. Krowka MJ, Cortese DA. Hepatopulmonary syndrome: current concepts in diagnostic and therapeutic considerations. Chest 1994; 105:1528-1537
81. Krowka MJ. Hepatopulmonary syndrome vs portopulmonary hypertension: distinctions and dilemmas. Hepatology 1997; 25:1282-1284
82. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000; 6:453-458
83. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation 2001; 71:572-574
84. Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6:443-450
85. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000; 162:1577-1586
86. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999; 155:411-419
87. Yaginuma G, Mohri H, Takahashi T. Distribution of arterial lesions and collateral pathways in the pulmonary hypertension of congenital heart disease: a computer aided reconstruction study. Thorax 1990; 45:586-590
88. Ogata T, Iijima T. Structure and pathogenesis of plexiform lesion in pulmonary hypertension. Chin Med J (Engl) 1993; 106:45-48
89. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80:1198-1206
90. Mason NA, Springall DR, Burke M, et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol 1998; 185:313-318
91. Kibria G, Smith P, Heath D, et al. Observations on the rare association between portal and pulmonary hypertension. Thorax 1980; 35:945-949
92. Hiyama E. Pulmonary vascular changes after portasystemic shunt operation in rats [in Japanese]. Nippon Geka Gakkai Zasshi 1989; 90:874-885
93. Tuder RM, Cool CD, Yeager M, et al. The pathobiology of pulmonary hypertension: endothelium. Clin Chest Med 2001; 22:405-418
94. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001; 88:E2-E11
95. Higenbottam TW, Laude EA. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles F. Filley lecture. Chest 1998; 114:72S-79S
96. Fishman AP. Etiology and pathogenesis of primary pulmonary hypertension: a perspective. Chest 1998; 114:242S-247S
97. Welsh CH, Hassell KL, Badesch DB, et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110:710-717
98. 2. J Appl Physiol 1980; 49:107-112
99. Geraci MW, Gao B, Shepherd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999; 103:1509-1515
100. Hara S, Morishita R, Tone Y, et al. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem Biophys Res Commun 1995; 216:862-867
101. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75
102. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159:1925-1932
103. Hassoun PM, Thappa V, Landman MJ, et al. Endothelin 1 mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med 1992; 199:165-170
104. Stelzner TJ, O'Brien RF, Yanagisawa M, et al. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 1992; 260:L614-L620
105. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. Circulation 1991; 84:2280-2285
106. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85:504-509
107. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114:464-469
108. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739
109. Vincent JA, Ross RD, Kassab J, et al. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am J Cardiol 1993; 71:1204-1207
110. Chang H, Wu GJ, Wang SM, et al. Plasma endothelin levels and surgically correctable pulmonary hypertension. Ann Thorac Surg 1993; 55:450-458
111. Kamath PS, Tyce GM, Miller VM, et al Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999; 30:401-407
112. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327:1774-1778
113. Zhan Q, Guo J, Tang J, et al. Alternation of the level of plasma calcitonin gene related peptide and endothelin-1 in liver cirrhosis [in Chinese]. Zhonghua Nei Ke Za Zhi 1999; 38:91-93
114. Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117:1222-1228
115. Cella G, Bellotto F, Tona F, et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120:1226-1230
116. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15:277-280
117. Morse JH, Jones AC, Barst RJ, et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95:2603-2606
118. Thomas AQ, Gaddipati R, Newman JH, et al. Genetics of primary pulmonary hypertension. Clin Chest Med 2001; 22:477-491,ix
119. Geraci MW, Moore M, Gesell T, et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 2001; 88:555-562
120. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-1150
121. Flemale A, Sabot JP, Popijn M, et al. Pulmonary hypertension associated with portal thrombosis. Eur J Respir Dis 1985; 66:224-228
122. Jones FD, Kuo PC, Johnson LB, et al. The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Anesthesiology 1999; 90:626-629
123. Kaspar MD, Ramsay MA, Shuey CB Jr, et al. Severe pulmonary hypertension and amelioration of hepatopulmonary syndrome after liver transplantation. Liver Transpl Surg 1998; 4:177-179
124. Mal H, Burgiere O, Durand F, et al. Pulmonary hypertension following hepatopulmonary syndrome in a patient with cirrhosis. J Hepatol 1999; 31:360-364
125. Martinez-Palli G, Barbera JA, Taura P, et al. Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome. J Hepatol 1999; 31:1075-1079
126. Gosney JR, Resl M. Pulmonary endocrine cells in plexogenic pulmonary arteriopathy associated with cirrhosis. Thorax 1995; 50:92-93
127. Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999; 54:161-168
128. Lee SL, Wang WW, Lanzillo JJ, et al. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994; 266:L46-L52
129. Eddahibi S, Chouaid C, Sediame S, et al. Serotonin uptake and citalopram binding in platelets from patients with chronic pulmonary hypertension [abstract]. Am J Respir Crit Care Med 1999; 159:A165
130. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99:249-254
131. Laffi G, Marra F, Gresele P, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992; 103:641-646
132. Senior RM, Britton RC, Turino GM, et al. Pulmonary hypertension associated with cirrhosis of the liver and with portacaval shunts. Circulation 1968; 37:88-96
133. Lai KS, McFadzean AJ, Yeung R. Microembolic pulmonary hypertension in pyogenic cholangitis. BMJ 1968; 1:22-24
134. Lal S, Fletcher E. Pulmonary hypertension and portal venous system thrombosis. Br Heart J 1968; 30:723-725
135. Larrey D, Theodore C, Molas G, et al. Primary biliary cirrhosis and pulmonary arterial hypertension [in French]. Gastroenterol Clin Biol 1981; 5:588-589
136. Wallwork J, Williams R, Calne RY. Transplantation of liver, heart, and lungs for primary biliary cirrhosis and primary pulmonary hypertension. Lancet 1987; 2:182-185
137. Mansour M, Lassabe G, Rauscher M, et al. Pulmonary arterial hypertension and primary biliary cirrhosis [in French]. Arch Mal Coeur Vaiss 1995; 88:503-505
138. Koenig A, Dietle A, Chauvin M, et al. Primary pulmonary arterial hypertension associated with primary biliary cirrhosis [letter in French]. Presse Med 1998; 27:1329
139. Aoki A, Kenmochi H, Hagiwara E, et al. Pulmonary hypertension in a patient with primary Sjögren's syndrome, Hashimoto's disease, and primary biliary cirrhosis [in Japanese]. Nihon Rinsho Meneki Gakkai Kaishi 2000; 23:462-469
140. Yuan JX, Aldinger AM, Juhaszova M, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98:1400-1406
141. Carter EP, Sato K, Morio Y, et al. Inhibition of K(Ca) channels restores blunted hypoxic pulmonary vasoconstriction in rats with cirrhosis. Am J Physiol Lung Cell Mol Physiol 2000; 279:L903-L910
142. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63:604-606
143. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-804
144. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34:1188-1192
145. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870
146. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104:1218-1222
147. Nagaya N, Uematsu M, Oya H, et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2001; 163:887-891
148. Findlay JY, Harrison BA, Plevak DJ, et al. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg 1999; 5:381-387
149. Buchhorn R, Hulpke-Wette M, Wessel A, et al. β-Blocker therapy in an infant with pulmonary hypertension. Eur J Pediatr 1999; 158:1007-1008
150. Ribas J, Angrill J, Barbera JA, et al. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999; 13:210-212
151. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903
152. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-a receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-1868
153. Dennis CM, McNeil KD, Dunning J, et al. Heart-lung-liver transplantation. J Heart Lung Transplant 1996; 15:536-538
154. Pirenne J, Verleden G, Nevens F, et al. Combined liver and (heart-) lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. Transplantation 2002; 73:140-142
155. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81
156. Vorob'ev LP, Maev IV, Andreev NG. Drug therapy of pulmonary and portal hypertension in liver cirrhosis [in Russian]. Klin Med (Mosk) 1991; 69:64-67
157. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999; 116:914-920
158. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740-743
159. Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30:641-648
160. Schroeder RA, Rafii AA, Plotkin JS, et al. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. Transplantation 2000; 70:548-550
161. De Wolf AM, Scott VL, Gasior T, et al. Pulmonary hypertension and liver transplantation. Anesthesiology 1993; 78:213-214
162. Bozkurt S, Ersoy E, Tekyn HE, et al. The cytoprotective effect of iloprost against carbon tetrachloride induced necrosis in rat liver. Res Commun Mol Pathol Pharmacol 1997; 95:343-346
163. Davies DS, Fawthrop DJ, Nasseri-Sina P, et al. Paracetamol toxicity and its prevention by cytoprotection with iloprost. Toxicol Lett 1992; 64-65 Spec No: 575-580
164. Nasseri-Sina P, Fawthrop DJ, Wilson J, et al. Cytoprotection by iloprost against paracetamol-induced toxicity in hamster isolated hepatocytes. Br J Pharmacol 1992; 105:417-423
165. Findlay JY, Plevak DJ, Krowka MJ, et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999; 5:362-365
166. Tilton RG, Munsch CL, Sherwood SJ, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther 2000; 13:87-97
167. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102:411-418
168. De Wolf AM, Scott V, Bjerke R, et al. Hemodynamic effects of inhaled nitric oxide in four patients with severe liver disease and pulmonary hypertension. Liver Transpl Surg 1997; 3:594-597
169. Ramsay MA, Schmidt A, Hein HA, et al. Nitric oxide does not reverse pulmonary hypertension associated with end-stage liver disease: a preliminary report. Hepatology 1997; 25:524-527
170. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84:E4
171. Schumacher YO, Zdebik A, Huonker M, et al. Sildenafil in HIV-related pulmonary, hypertension. AIDS 2001; 15:1747-1748
172. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104:424-428
173. Sanders DB, Kelley T, Larson D. The role of nitric oxide synthase/nitric oxide in vascular smooth muscle control. Perfusion 2000; 15:97-104
174. Langle F, Roth E, Steininger R, et al. Arginase release following liver reperfusion: evidence of hemodynamic action of arginase infusions. Transplantation 1995; 59:1542-1549
175. Kobayashi H, Nonami T, Kurokawa T, et al. Role of endogenous nitric oxide in ischemia-reperfusion injury in rat liver. J Surg Res 1995; 59:772-779
176. Shimamura T, Zhu Y, Zhang S, et al. Protective role of nitric oxide in ischemia and reperfusion injury of the liver. J Am Coll Surg 1999; 188:43-52
177. Shiraishi M, Hiroyasu S, Nagahama M, et al. Role of exogenous L-arginine in hepatic ischemia-reperfusion injury. J Surg Res 1997; 69:429-434
178. Nilsson B, Yoshida T, Delbro D, et al. Pretreatment with L-arginine reduces ischemia/reperfusion injury of the liver. Transplant Proc 1997; 29:3111-3112
179. Higa T, Shiraishi M, Mamadi T, et al. Limitations of exogenous L-arginine in exerting a cytoprotective effect on hepatic ischemia/reperfusion injury. Surg Today 2000; 30:352-359
180. Scott V, De Wolf A, Kang Y, et al. Reversibility of pulmonary hypertension after liver transplantation: a case report. Transplant Proc 1993; 25:1789-1790
181. Losay J, Piot D, Bougaran J, et al. Early liver transplantation is crucial in children with liver disease and pulmonary artery hypertension. J Hepatol 1998; 28:337-342
182. Schott R, Chaouat A, Launoy A, et al. Improvement of pulmonary hypertension after liver transplantation. Chest 1999; 115:1748-1749
183. Plevak D, Krowka M, Rettke S, et al. Successful liver transplantation in patients with mild to moderate pulmonary hypertension [letter]. Transplant Proc 1993; 25:1840
184. Rafanan AL, Maurer J, Mehta AC, et al. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000; 118:1497-1500
185. Mandell MS, Groves BM, Duke J. Progressive plexogenic pulmonary hypertension following liver transplantation. Transplantation 1995; 59:1488-1490
186. Prager MC, Cauldwell CA, Ascher NL, et al. Pulmonary hypertension associated with liver disease is not reversible after liver transplantation. Anesthesiology 1992; 77:375-378
187. Kett DH, Acosta RC, Campos MA, et al. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 2001; 7:645-648
188. Plotkin JS, Kuo PC, Rubin LJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65:457-459
189. Tan HP, Markowitz JS, Montgomery RA, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001; 7:745-749
190. Kahler CM, Graziadei I, Wiedermann CJ, et al. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 2000; 112:637-640
191. Neumann UP, Kaisers U, Langrehr JM, et al. Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial. Clin Transplant 2000; 14:70-74
192. Csete M. Intraoperative management of liver transplant patients with pulmonary hypertension. Liver Transpl Surg 1997; 3:454-455
193. Kinirons B, Kuhlman L, Mori K, et al. Management of peri-operative pulmonalry hypertension in a patient presenting for a portosystemic shunt. Eur J Anaesthesiol 1999; 16:728-732
194. Tarquino M, Geggel RL, Strauss RS, et al. Treatment of pulmonary hypertension with inhaled nitric oxide during hepatic transplantation in an adolescent: reversibility of pulmonary hypertension after transplantation. Clin Pediatr (Phila) 1998; 37:505-509
195. Cheng DC, Edelist G. Isoflurane and primary pulmonary hypertension. Anaesthesia 1988; 43:22-24
196. Rettke SR, Chantigian RC, Janossy TA, et al. Anesthesia approach to hepatic transplantation. Mayo Clin Proc 1989; 64:224-231
197. Cheng EY, Woehlck HJ. Pulmonary artery hypertension complicating anesthesia for liver transplantation. Anesthesiology 1992; 77:389-392
198. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161:487-492
199. Waxman AB. Pulmonary function test abnormalities in pulmonary vascular disease and chronic heart failure. Clin Chest Med 2001; 22:751-758
200. Rhodes J, Barst RJ, Garofano RP, et al. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol 1991; 18:1738-1744
201. D'Alonzo GE, Gianotti L, Dantzker DR. Noninvasive assessment of hemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension. Am Rev Respir Dis 1986; 133:380-384
202. Geraci MW, Gao B, Hoshikawa Y, et al. Genomic approaches to research in pulmonary hypertension. Respir Res 2001; 2:210-215
203. Janssens SP, Bloch KD, Nong Z, et al. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest 1996; 98:317-324
204. Nagaya N, Yokoyama C, Kyotani S, et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 2000; 102:2005-2010
205. Champion HC, Bivalacqua TJ, Toyoda K, et al. In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation 2000; 101:923-930
206. Louzier V, Eddahibi S, Raffestin B, et al. Adenovirus-mediated. atrial natriuretic protein expression in the lung protects rats from hypoxia-induced pulmonary hypertension. Hum Gene Ther 2001; 12:503-513
207. Campbell AI, Zhao Y, Sandhu R, et al. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001; 104:2242-2248
208. Mandall MS, Krowka MJ. Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease. Anesthesiology 1997; 87:450-451